2. Academic Validation
  3. Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR)

Pyrazolo[3,4-d]pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR)

  • Bioorg Med Chem Lett. 2007 Oct 1;17(19):5406-9. doi: 10.1016/j.bmcl.2007.07.037.
Robert D Hubbard 1,  Nwe Y Bamaung,  Fabio Palazzo,  Qian Zhang,  Peter Kovar,  Donald J Osterling,  Xiaoming Hu,  Julie L Wilsbacher,  Eric F Johnson,  Jennifer Bouska,  Jieyi Wang,  Randy L Bell,  Steven K Davidsen,  George S Sheppard
Affiliations

Affiliation

  • 1 Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. robert.d.hubbard@abbott.com
PMID: 17689078 DOI: 10.1016/j.bmcl.2007.07.037
Abstract

A high throughput screen of Abbott's compound repository revealed that the pyrazolo[3,4-d]pyrimidine class of kinase inhibitors possessed moderate potency for IGF-IR, a promising target for Cancer chemotherapy. The synthesis and subsequent optimization of this class of compounds led to the discovery of 14, a compound that possesses in vivo IGF-IR inhibitory activity.

Figures